Haifa Kathrin Al-Ali

, Christina Zahn, Nicole Nedlitz, Gabriele Prange-Krex, Johannes Mohm, Bettina Peuser, Maik Schwarz, Claudia Spohn, Timo Behlendorf, Mascha Binder and 3 other authors

Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO)

Download from doi.org

Saskia Hell, Madlen Jentzsch, Georg-Nikolaus Franke

, Nadja Jäkel, Susann Schulze, Jeanett Edelmann, Kolja Nenoff, Nora Grieb, Veljko Jeremic, Michael Cross, Sabine Leiblein, Enrica Bach, Wolfram Pönisch, Haifa-Kathrin Al-Ali

, Sebastian Schwind

and 4 other authors

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15

Download from www.nature.com

This paper was not found in any repository, but could be made available legally by the author.

2020 Haifa Kathrin Al‐Ali

, Martin Griesshammer

, Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, Anna Marina Liberati, Philipp Coutre, Carmen García‐Hernández, Andrey Zaritskey, Renato Tavares, Vikas Gupta, Pia Raanani, Pilar Giraldo, Mathias Hänel and 7 other authors

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Upload

2019 Christin Le Hoa Tran

, Nadja Jaekel, Marcus Bauer, Alexander Emmer, Claudia Wickenhauser, Haifa Kathrin Al-Ali

Aggressive systemic mastocytosis: a diagnostic challenge in a patient with myotonic dystrophy type 2: a case report

Download from link.springer.com

2017 John F. Seymour

, Hartmut Döhner, Aleksandra Butrym, Agnieszka Wierzbowska

, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali

, Jose Falantes and 6 other authors

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Download from link.springer.com

A. Tefferi, H. K. Al-Ali

, G. Barosi, T. Devos, H. Gisslinger, Q. Jiang, J.-J. Kiladjian, R. Mesa, F. Passamonti, M. F. McMullin, V. Ribrag, G. Schiller, A. M. Vannucchi, D. Zhou, D. Reiser and 2 other authors

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Download from www.nature.com

Antonio M. Almeida, Thomas Prebet, Raphael Itzykson, Fernando Ramos, Haifa Al-Ali

, Jamile Shammo, Ricardo Pinto, Luca Maurillo

, Jaime Wetzel, Pellegrino Musto, Arjan A. Van De Loosdrecht, Maria J. Costa, Susana Esteves

, Sonja Burgstaller, Reinhard Stauder and 19 other authors

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Download from doi.org

Wolfram Poenisch, Natalie Wehde, Gudrun Borte, Andre Liebmann, HaifaKathrin Al-Ali

, DietgerWalter Niederwieser

Primary mediastinal large B cell lymphoma: Frontline treatment with an alternating chemotherapy regimen based on high dose methotrexate - A single institution experience

Download from doi.org

2016 Martin Wermke, Claudia Schuster, Florian Nolte, Haifa-Kathrin Al-Ali

, Philipp Kiewe, Claudia Schönefeldt, Christiane Jakob, Malte von Bonin, Leopold Hentschel, Ina-Maria Klut, Gerhard Ehninger, Martin Bornhäuser, Gustavo Baretton, Ulrich Germing, Regina Herbst and 3 other authors

Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)

Download from api.wiley.com

V. Gupta

, C. Harrison, E. O. Hexner, H. K. Al-Ali

, L. Foltz, M. Montgomery, W. Sun, P. Gopalakrishna, H. Kantarjian, S. Verstovsek

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

Download from doi.org

H. K. Al-Ali

, M. Griesshammer, P. le Coutre, C. F. Waller

, A. M. Liberati, P. Schafhausen, R. Tavares, P. Giraldo, L. Foltz, P. Raanani, V. Gupta

, B. Tannir, J. P. Ronco, J. Ghosh, B. Martino and 1 other authors

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Download from doi.org

Haifa Kathrin Al-Ali

, Alessandro M. Vannucchi

Managing patients with myelofibrosis and low platelet counts

Upload

Haifa Kathrin Al-Ali

, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Julian Perez-Ronco, Lynda Foltz

Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis

Upload

C. N. Harrison, A. M. Vannucchi, J.-J. Kiladjian, H. K. Al-Ali

, H. Gisslinger, L. Knoops, F. Cervantes, M. M. Jones, K. Sun, M. McQuitty, V. Stalbovskaya, P. Gopalakrishna, T. Barbui

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Download from www.nature.com

This paper is available in a repository.

2015 C. Niederwieser, S. Starke, L. Fischer, R. Krahl, J. Beck, B. Gruhn, W. Ebell, D. Körholz, W. Wößmann, P. Bader, P. Lang, H.-K. Al Ali

, M. Cross, A.-K. Eisfeld, S. Heyn and 6 other authors

Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations

Download from www.researchgate.net

Christian Pfrepper, Anne Klink, Gerhard Behre, Thomas Schenk, Georg-Nikolaus Franke, Madlen Jentzsch, Sebastian Schwind, Haifa-Kathrin Al-Ali

, Andreas Hochhaus, Dietger Niederwieser, Herbert Gottfried Sayer

Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation

Upload

C. Kahl, R. Krahl, C. Becker, H. K. Al-Ali

, H. G. Sayer, A. Schulze, M. Herold, M. Hänel, S. Scholl, A. Hochhaus, L. Uharek, G. Maschmeyer, D. Haehling, C. Junghanß, N. Peter and 7 other authors

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

Upload